Amneal Pharmaceuticals (NASDAQ:AMRX) Director Sells $882,000.00 in Stock

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Director John Kiely sold 50,000 shares of the firm’s stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $17.64, for a total transaction of $882,000.00. Following the sale, the director directly owned 210,252 shares in the company, valued at $3,708,845.28. This represents a 19.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Amneal Pharmaceuticals Stock Performance

NASDAQ:AMRX opened at $18.15 on Monday. The firm has a 50 day simple moving average of $17.24 and a 200-day simple moving average of $14.60. The company has a debt-to-equity ratio of 77.65, a current ratio of 2.20 and a quick ratio of 1.44. The firm has a market cap of $5.80 billion, a PE ratio of 37.04 and a beta of 1.27. Amneal Pharmaceuticals, Inc. has a 1-year low of $9.20 and a 1-year high of $19.26.

Institutional Trading of Amneal Pharmaceuticals

Several institutional investors have recently made changes to their positions in AMRX. Westshore Wealth LLC purchased a new position in shares of Amneal Pharmaceuticals in the 3rd quarter worth about $13,833,000. Morgan Stanley grew its holdings in shares of Amneal Pharmaceuticals by 37.5% during the 4th quarter. Morgan Stanley now owns 4,818,099 shares of the company’s stock worth $60,708,000 after purchasing an additional 1,315,018 shares during the period. Allspring Global Investments Holdings LLC grew its holdings in shares of Amneal Pharmaceuticals by 72.2% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 2,549,572 shares of the company’s stock worth $32,405,000 after purchasing an additional 1,069,400 shares during the period. Bank of New York Mellon Corp acquired a new stake in Amneal Pharmaceuticals during the 2nd quarter worth approximately $17,573,000. Finally, Penn Capital Management Company LLC acquired a new stake in Amneal Pharmaceuticals during the 4th quarter worth approximately $12,655,000. 31.82% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

AMRX has been the topic of a number of recent analyst reports. Zacks Research raised Amneal Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Friday, August 7th. Barclays lifted their price objective on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research report on Wednesday, May 20th. UBS Group upped their target price on Amneal Pharmaceuticals from $23.00 to $25.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. Weiss Ratings downgraded Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Wednesday. Finally, The Goldman Sachs Group reissued a “buy” rating and issued a $21.00 price target on shares of Amneal Pharmaceuticals in a research note on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $17.67.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.